Categories Analysis, Health Care

Earnings preview: What to look for when Gilead reports Q2 results

Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts have forecast earnings of $1.72 per share on revenue of $5.51 billion.

Gilead’s top line results are expected to benefit from strength in the HIV product segment with momentum from Biktarvy in particular. HCV product sales are likely to see weakness, continuing the same trend as last quarter. Products like Odefsey, Vemlidy and Yescarta are likely to continue their growth trends in the second quarter.

Gilead Sciences Q1 2019 earnings results

Another area to watch is the company’s updates on its pipeline. Gilead is working on expanding the use of Descovy and Biktarvy in the treatment of HIV. The company also intends to file a new drug application for the approval of filgotinib in the treatment of rheumatoid arthritis. Gilead has entered into research partnerships with various companies for several products and updates on these alliances are also worth watching.

In the first quarter of 2019, Gilead topped market estimates. Revenues grew nearly 4% year-over-year to $5.3 billion while adjusted EPS rose 19% to $1.76. Sales in HIV Products grew 14% while sales in HCV Products dropped 24%. Sales of Other Products also fell 7%.

For fiscal year 2019, the company estimates its product sales to come in the range of $21.3 billion to $21.8 billion and adjusted product gross margin to come in the range of 85% to 87%.

Shares of Gilead have gained 9% so far this year and more than 3% over the past three months. The stock was up 0.91% during morning trade on Monday.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

TTWO Earnings: Take-Two Interactive slips to a loss in Q1; revenue up 36%

Gaming company Take-Two Interactive Software, Inc. (NASDAQ: TTWO) announced first-quarter 2023 results Monday after the closing bell, reporting a 36% revenue growth. First-quarter revenues rose 36% annually to $1.1 billion

Tyson Foods (TSN): Strong demand for beef and price hikes in chicken fuel Q3 top line growth

Shares of Tyson Foods Inc. (NYSE: TSN) plunged 9% on Monday after the company delivered mixed results for the third quarter of 2022. Revenues beat estimates while profits missed expectations.

TSN Earnings: All you need to know about Tyson Foods’ Q3 2022 earnings results

Tyson Foods, Inc. (NYSE: TSN) reported third quarter 2022 earnings results today. Sales rose to $13.5 billion from $12.5 billion in the same period a year ago. Net income attributable to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top